XML 59 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Segment Information (Tables)
6 Months Ended
Oct. 31, 2012
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 

Three Months Ended October 31, 2012   Personalized
Oncology
Solutions
(POS)
    Translational
Oncology
Solutions
(TOS)
    Unallocated
Corporate
Overhead
    Consolidated  
Net revenue   $ 459     $ 999     $ -     $ 1,458  
Direct cost of services     (576 )     (471 )     -       (1,047 )
Sales and marketing costs     (378 )     (241 )     -       (619 )
Other operating expenses     -       (433 )     (651 )     (1,084 )
Stock- based compensation expense (1)     -       -       (624 )     (624 )
                                 
Segment profit (loss)   $ (495 )   $ (146 )   $ (1,275 )   $ (1,916 )

 

Three Months Ended October 31, 2011   Personalized
Oncology
Solutions
(POS)
    Translational
Oncology
Solutions
(TOS)
    Unallocated
Corporate
Overhead
    Consolidated  
Net revenue   $ 590     $ 1,151     $ -     $ 1,741  
Direct cost of services     (461 )     (604 )     -       (1,065 )
Sales and marketing costs     (369 )     (221 )     -       (590 )
Other operating expenses     -       (984 )     (716 )     (1,700 )
Stock- based compensation expense (1)     -       -       (855 )     (855 )
                                 
Segment profit (loss)   $ (240 )   $ (658 )   $ (1,571 )   $ (2,469 )

 

Six Months Ended October 31, 2012   Personalized
Oncology
Solutions
(POS)
    Translational
Oncology
Solutions
(TOS)
    Unallocated
Corporate
Overhead
    Consolidated  
Net revenue   $ 1,377     $ 2,187     $ -     $ 3,564  
Direct cost of services     (1,293 )     (1,162 )     -       (2,455 )
Sales and marketing costs     (814 )     (432 )     -       (1,246 )
Other operating expenses     -       (794 )     (1,221 )     (2,015 )
Stock- based compensation expense (1)     -       -       (1,364 )     (1,364 )
                                 
Segment profit (loss)   $ (730 )   $ (201 )   $ (2,585 )   $ (3,516 )

 

Six Months Ended October 31, 2011   Personalized
Oncology
Solutions
(POS)
    Translational
Oncology
Solutions
(TOS)
    Unallocated
Corporate
Overhead
    Consolidated  
Net revenue   $ 1,188     $ 2,184     $ -     $ 3,372  
Direct cost of services     (945 )     (1,072 )     -       (2,017 )
Sales and marketing costs     (676 )     (466 )     -       (1,142 )
Other operating expenses     -       (1,568 )     (1,462 )     (3,030 )
Stock- based compensation expense (1)     -       -       (1,868 )     (1,868 )
                                 
Segment profit (loss)   $ (433 )   $ (922 )   $ (3,330 )   $ (4,685 )

 

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.